Breathing Disorders Treatment Market Research Report - Global Forecast till 2027

Breathing Disorders Treatment Market Research Report: By Drug Type (Antibiotics, Non-Steroidal Anti-Inflammatory Drug [NSAIDS], Cough Suppressant, Nasal Decongestant and others), Indication (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Allergic Rhinitis, Pulmonary Hypertension, Cystic Fibrosis (CF), Idiopathic Pulmonary Fibrosis and others), End User (Hospitals and Clinics, Retail Pharmacies and Online Pharmacies) and by Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/1046-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2019–2025 to 2020-2027. Cordially fill Sample form for updated data.

Market Scenario


The Global Breathing Disorders Treatment Market is expected to register a 7.5% CAGR during the forecast period. Breathing disorders are the one that affects the lungs and other parts of respiratory system. These breathing disorders include chronic sinusitis, asthma, and chest congestion. The person suffering from breathing problems faces various symptoms such as runny nose, nasal congestion, itchy or watery eyes, cough, chest congestion, labored breathing, wheezing, and shallow breathing. The primary factors driving the growth of global breathing disorder & treatment market are increasing allergic reaction that causes breathing problem, pollen grain reaction, low blood pressure, or hypertension in individuals.


According to the World Health Organization, it was estimated, that 383,000 people died due to asthma in 2015. The rising prevalence of asthma among the population is likely to boost the market growth.


However, stringent government regulation related to drug launch, side effects, and allergic reactions due to steroids may hinder the market growth during the forecasted period


Segmentation


The global breathing disorders treatment market has been segmented into drug class, indication, and end users.


By drug class the market has been segmented into antibiotics, non-steroidal anti-inflammatory drug (NSAIDS), cough suppressant, nasal decongestant, and others.


 On the basis of indication, the market has been segmented into allergic rhinitis, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF), pulmonary hypertension, idiopathic pulmonary fibrosis and others.


On the basis of end user, the market has been segmented into hospital, clinics, retail pharmacies, and online pharmacies.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The breathing disorders treatment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European breathing disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The breathing disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, Latin Korea, Australia, and the rest of Asia-Pacific. The breathing disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key Players



  • AstraZeneca

  • GlaxoSmithKline

  • Merck Sharp & Dohme Corp.

  • Abbott

  • Medtronic plc

  • Hoffmann-La Roche Ltd

  • Novartis AG

  • Reddy’s Laboratories

  • Amgen

  • Aurobindo Pharma.

  • Bayer AG

  • Biogen

  • Others


Regional Market Summary


Global Breathing disorders treatment Market Share (%), by Region, 2018  Breathing disorders treatment Market


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports


Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. It is estimated that Americas dominated the global breathing disorders treatment market owing to the increasing prevalence of respiratory disorders, rising geriatric population and heart-related problems. According to the Centers for Disease Control and Prevention 2017, 8.9 million adults were diagnosed with chronic bronchitis in the US and 135,268 number of deaths occurred due to chronic lower respiratory diseases. Such high prevalence of respiratory diseases in the US is expected to boost the market growth in America.


Europe stood second largest in the breathing disorders treatment market owing to the increasing health problems such as hypertension, stress, obesity, and changing lifestyle among the population. The increase pollution and environmental changes are also contributing in the demand for breathing treatment.  According, to the article published on NHS Digital 617,000 patients were under treatment in NHS hospitals because of obesity in 2016. The increasing obesity leads to cause breathing problems and hyperventilation to the patient, which will increase the demand for breathing treatment.


Asia-Pacific was anticipated to be the rapidly growing region for the breathing disorders treatment market. The market is expected to witness growth owing to the increasing population and rising demand for pharmaceutical products required for the treatment of asthma, chronic obstructive pulmonary disease (COPD), wheezing, and other breathing-related disorders. The prevalence of asthma is high in developing countries and cities, such as Japan, Hong Kong, and Singapore which support the market growth.


The market in the Middle East and Africa holds a low share in the global breathing disorders treatment market due to the presence of a low number of healthcare facilities, low per capita income and people living in underdeveloped countries are not much aware of the upcoming treatment methods. However, the market is expected to witness growth due to increasing hospitals and rising demand for the products in the Middle East.


Global Breathing disorders treatment Market, by Drug Type



  • Antibiotics

  • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

  • Cough Suppressant

  • Nasal Decongestant

  • Others


Global Breathing disorders treatment Market, by Indication



  • Chronic Obstructive Pulmonary Disease (COPD)

  • Asthma

  • Allergic Rhinitis

  • Pulmonary Hypertension

  • Cystic Fibrosis (CF)

  • Idiopathic Pulmonary Fibrosis

  • Others


Global Breathing disorders treatment Market, by End User



  • Hospital and Clinics

  • Retail Pharmacies

  • Online Pharmacies


Global Breathing disorders treatment Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • Latin Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Bipolar Disorders and Treatment centers

  • Contract Research Organizations (CROs)

  • Research and Development (R&D) Companies

  • Government Research Laboratories

  • Independent Research Laboratories

  • Government and Independent Regulatory Authorities

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   7.5% (2019–2025)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Type, Indication and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Abbott, Medtronic plc, Hoffmann-La Roche Ltd, Novartis AG, Reddy’s Laboratories, Amgen, Aurobindo Pharma., Bayer AG, Biogen
  Key Market Opportunities   The rising prevalence of asthma among the population
  Key Market Drivers

  • increasing allergic reaction that causes breathing problem
  • pollen grain reaction
  • low blood pressure
  • hypertension in individuals


  • Frequently Asked Questions (FAQ) :


    Breathing disorders treatment market CAGR would be 7.5% during the forecast period.

    Strict regulations, side-effects, and allergic reactions can hold back Breathing disorders treatment market.

    Breathing disorders treatment market hospitals, clinics, retail pharmacies, and online pharmacies.

    Breathing disorders treatment market has indications like chronic obstructive pulmonary disease (COPD), allergic rhinitis, cystic fibrosis (CF), asthma, idiopathic pulmonary fibrosis, pulmonary hypertension, and others.

    The Americas would lead the breathing disorders treatment market.

    Table of Content

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    Chapter 6. Global Breathing Disorders Treatment Market, by Drug Type

    6.1 Introduction

    6.2 Antibiotics

    6.3 Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

    6.4 Cough Suppressant

    6.5 Nasal Decongestant

    6.6 Others

    Chapter 7. Global Breathing Disorders Treatment Market, by Indication

    7.1 Introduction

    7.2 Chronic Obstructive Pulmonary Disease (COPD)

    7.3 Asthma

    7.4 Allergic Rhinitis

    7.5 Pulmonary Hypertension

    7.6 Cystic Fibrosis (CF)

    7.7 Idiopathic Pulmonary Fibrosis

    7.7 Others

    Chapter 8. Global Bipolar Disorders and Treatment Market, by End User

    8.1 Introduction

    8.2 Hospitals and Clinics

    9.3 Retail Pharmacies

    8.4 Online Pharmacies

    Chapter 9. Global Breathing Disorders Treatment Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 Latin America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 Middle East

    9.5.2 Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    Chapter 11 Company Profiles

    11.1 AstraZeneca

    11.1.1 Company Overview

    11.1.2 Type Overview

    11.1.3 Financials Overview

    11.1.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Medtronic plc

    11.2.1 Company Overview

    11.2.2 Type Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 GlaxoSmithKline Plc.

    11.3.1 Company Overview

    11.3.2 Type Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Merck Sharp & Dohme Corp.

    11.4.1 Company Overview

    11.4.2 Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 F. Hoffmann-La Roche Ltd

    11.5.1 Company Overview

    11.5.2 Type Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 Novartis AG

    11.6.1 Company Overview

    11.6.2 Type Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Abbott

    11.7.1 Overview

    11.7.2 Type Overview

    11.7.3 Financial Overview

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Dr. Reddy’s Laboratories

    11.8.1 Overview

    11.8.2 Type Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 Amgen

    11.9.1 Overview

    11.9.2 Type Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.10 Aurobindo Pharma.

    11.10.1 Overview

    11.10.2 Type Overview

    11.10.3 Financials

    11.10.4 Key Developments

    11.10.5 SWOT Analysis

    11.11 Bayer AG

    11.11.1 Overview

    11.11.2 Type Overview

    11.11.3 Financials

    11.11.4 Key Developments

    11.11.5 SWOT Analysis

    11.12 Biogen

    11.12.1 Overview

    11.12.2 Type Overview

    11.12.3 Financials

    11.12.4 Key Developments

    11.12.5 SWOT Analysis

    11.13 Others

    Chapter 12. Appendix

    LIST OF TABLES

    Table 1 Global Breathing Disorders Treatment Synopsis, 2020-2027

    Table 2 Global Breathing Disorders Treatment Market Estimates and Forecast, 2020-2027, (USD Million)

    Table 3 Global Breathing Disorders Treatment Market, by Region 2020-2027, (USD Million)

    Table 4 Global Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 5 Global Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 6 Global Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 7 North America: Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 8 North America: Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 9 North America: Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 10 US: Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 11 US: Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 12 US: Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 13 Canada: Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 14 Canada: Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 15 Canada: Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 16 Latin America: Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 17 Latin America: Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 18 Latin America: Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 19 Europe: Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 20 Europe: Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 21 Europe: Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 22 Western Europe: Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 23 Western Europe: Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 24 Western Europe: Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 25 Eastern Europe: Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 26 Eastern Europe: Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 27 Eastern Europe: Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 28 Asia-Pacific: Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 29 Asia-Pacific: Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 30 Asia-Pacific: Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 31 Middle East & Africa: Breathing Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 32 Middle East & Africa: Breathing Disorders Treatment Market, by Indication 2020-2027, (USD Million)

    Table 33 Middle East & Africa: Breathing Disorders Treatment Market, by End User 2020-2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Breathing Disorders Treatment Market

    Figure 3 Segmentation Market Dynamics for Global Breathing Disorders Treatment Market

    Figure 4 Global Breathing Disorders Treatment Market Share, by Drug Type, 2020

    Figure 5 Global Breathing Disorders Treatment Market Share, by Indication, 2020

    Figure 6 Global Breathing Disorders Treatment Market Share, by End User, 2020

    Figure 7 Global Breathing Disorders Treatment Market Share, by Region, 2020

    Figure 8 North America: Breathing Disorders Treatment Market Share, by Country, 2020

    Figure 9 Europe: Breathing Disorders Treatment Market Share, by Country, 2020

    Figure 10 Asia-Pacific: Breathing Disorders Treatment Market Share, by Country, 2020

    Figure 11 Middle East & Africa: Breathing Disorders Treatment Market Share, by Country, 2020

    Figure 12 Global Breathing Disorders Treatment Market: Company Share Analysis, 2020 (%)

    Figure 13 Medtronic plc: Key Financials

    Figure 14 Medtronic plc: Segmental Revenue

    Figure 15 Medtronic plc: Geographical Revenue

    Figure 16 Novartis AG: Key Financials

    Figure 17 Novartis AG: Segmental Revenue

    Figure 18 Novartis AG: Geographical Revenue

    Figure 19 AstraZeneca: Key Financials

    Figure 20 AstraZeneca.: Segmental Revenue

    Figure 21 AstraZeneca: Geographical Revenue

    Figure 22 Merck: Key Financials

    Figure 23 Merck: Segmental Revenue

    Figure 24 Merck: Geographical Revenue

    Figure 25 GlaxoSmithKline: Key Financials

    Figure 26 GlaxoSmithKline: Segmental Revenue

    Figure 27 GlaxoSmithKline: Geographical Revenue

    Figure 28 Abbott: Key Financials

    Figure 29 Abbott: Segmental Revenue

    Figure 30 Abbott: Geographical Revenue

    Figure 31 Dr. Reddy’s Laboratories: Key Financials

    Figure 32 Dr. Reddy’s Laboratories: Segmental Revenue

    Figure 33 Dr. Reddy’s Laboratories: Geographical Revenue

    Figure 34 Amgen: Key Financials

    Figure 35 Amgen: Segmental Revenue

    Figure 36 Amgen: Geographical Revenue

    Figure 37 Pfizer Inc.: Key Financials

    Figure 38 Pfizer Inc.: Segmental Revenue

    Figure 39 Pfizer Inc.: Geographical Revenue

    Figure 40 Aurobindo Pharma.: Key Financials

    Figure 41 Aurobindo Pharma.: Segmental Revenue

    Figure 42 Aurobindo Pharma.: Geographical Revenue

    Figure 43 Bayer AG: Key Financials

    Figure 44 Bayer AG.: Segmental Revenue

    Figure 45 Bayer AG.: Geographical Revenue

    Figure 46 Biogen: Key Financials

    Figure 47 Biogen: Segmental Revenue

    Figure 48 Biogen: Geographical Revenue